Summit Therapeutics's total assets for Q1 2026 were £647.86M, a decrease of -13.76% from the previous quarter. SMMT total liabilities were £101.92M for the fiscal quarter, a 10.40% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.